Celldex Therapeutics, Inc. — Director's Dealing 2008

Mar 20, 2008

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: AVANT IMMUNOTHERAPEUTICS INC (AVAN)
CIK: 0000744218
Period of Report: 2008-03-07

Reporting Person: Lorantis Holdings LTD (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2811147	Direct

Footnotes

F1: The Board of Directors of AVANT Immunotherapeutics, Inc. ("AVANT"), approved a 1-for 12 reverse stock split of AVANT's common stock, which became effective as of March 7, 2008. As a result of the reverse stock split, each twelve shares of AVANT common stock were combined and reclassified into one share of AVANT common stock. The number of shares reported on this form is reflected on a post-split basis. The common stock will trade under the symbol "AVAND" for 20 trading days beginning on March 10, 2008 to designate that it is trading on a post-reverse split basis, and will remain trading under the symbol "AVAN" after the 20-day period has expired.